尽管分析家意见不一,但生物基因和安根却看到股票购买激增,收入高涨。 Biogen and Amgen see surge in stock purchases and strong earnings, despite mixed analyst views.

机构投资者购买的生物基因公司股份大幅增加,包括West Oak Capital LLC增加了2000%。 Biogen Inc. saw a significant increase in shares purchased by institutional investors, including a 2,000% rise by West Oak Capital LLC. Biogen 报告了一份强劲的收益报告，超出预期，市值为 216.9 亿美元。 Biogen reported a strong earnings report, beating estimates and has a market cap of $21.69 billion. 同时,Amgen公司也报告收入丰厚,季度收入增加23.2%,季度红利增加。 Meanwhile, Amgen Inc. also reported strong earnings, with a 23.2% increase in quarterly revenue and a boost in its quarterly dividend. 尽管分析家的评分不一,但两家公司仍然侧重于发展各种疾病的治疗方法。 Despite mixed analyst ratings, both companies remain focused on developing therapies for various diseases.